These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 15026800)

  • 21. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
    Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the use of irinotecan in colorectal cancer.
    Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
    Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
    J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
    McGavin JK; Goa KL
    Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
    Twelves C; Scheithauer W; McKendrick J; Seitz JF; Van Hazel G; Wong A; Díaz-Rubio E; Gilberg F; Cassidy J
    Ann Oncol; 2012 May; 23(5):1190-1197. PubMed ID: 21896539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
    J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential regional differences for the tolerability profiles of fluoropyrimidines.
    Haller DG; Cassidy J; Clarke SJ; Cunningham D; Van Cutsem E; Hoff PM; Rothenberg ML; Saltz LB; Schmoll HJ; Allegra C; Bertino JR; Douillard JY; Gustavsson BG; Milano G; O'Connell M; Rustum Y; Tabernero J; Gilberg F; Sirzén F; Twelves C
    J Clin Oncol; 2008 May; 26(13):2118-23. PubMed ID: 18445840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.